cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.x5kyv8
title: Occurrence Download

description: A dataset containing 10073 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Abies ernestii Rehd., Abies faxoniana Rehd. & E.H.Wilson, Abies ferreana Bordères & Gaussen, Abies fordei Rushforth, Abies georgei Orr, Abies minensis Bordères & Gaussen, Abies salouenensis Bordères & Gaussen, Abies sikokiana Nakai, Cephalotaxus Siebold & Zucc. ex Endl., Cephalotaxus wilsoniana Hayata)",
 "HasCoordinate is true",
 "Year is greater than 1900"
 ]
}

 The dataset includes 10073 records from 292 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055908-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cwd4w5
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Apatococcus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is one of (Specimen, Living Specimen, Observation, Human Observation, Machine Observation, Material sample, Literature Occurrence, Material citation, Occurrence evidence)",
 "Geometry POLYGON ((20.2855 -34.7533,20.509 -34.5676,20.509 -32.9007,17.7723 -32.9007,17.8156 -33.0786,18.3471 -33.7176,18.3748 -33.8287,18.2181 -34.0492,18.3197 -34.3408,18.4452 -34.429,18.5435 -34.4213,18.5872 -34.3667,18.5363 -34.167,18.7345 -34.1508,18.7216 -34.3637,18.7808 -34.4521,19.0289 -34.4206,19.0831 -34.4835,19.2655 -34.5017,19.2032 -34.6157,19.2394 -34.6926,19.375 -34.6963,19.6091 -34.8524,19.8251 -34.8396,19.9798 -34.9064,20.1081 -34.8731,20.1517 -34.7847,20.2855 -34.7533))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055909-250525065834625/datasets/export for details.
DOI: 10.15468/dl.wu8tv8
title: Occurrence Download

description: A dataset containing 12 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is one of (South America, North America)",
 "Country is one of (Canada, Colombia, Argentina, Bolivia (Plurinational State of), Brazil, Paraguay)",
 "TaxonKey is Panthera pardus (Linnaeus, 1758)"
 ]
}

 The dataset includes 12 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055910-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.15682211
title: PV isotherm of LTA

description: The data set is the output file from the scanning transitiometer used to determine the heat of intrusion into LTA silica. The intrusion liquid is water.
DOI: 10.5281/zenodo.15682212
title: PV isotherm of LTA

description: The data set is the output file from the scanning transitiometer used to determine the heat of intrusion into LTA silica. The intrusion liquid is water.
DOI: 10.15468/dl.w4mwe3
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Apatococcus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is one of (Specimen, Living Specimen, Observation, Human Observation, Machine Observation, Material sample, Literature Occurrence, Material citation, Occurrence evidence)",
 "Geometry POLYGON ((35.628 -23.023,35.6007 -22.9702,35.6007 -23.165,35.628 -23.023))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055912-250525065834625/datasets/export for details.
DOI: 10.15468/dl.4sjt45
title: Occurrence Download

description: A dataset containing 735 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "OccurrenceStatus is Present",
 "TaxonKey is Ginkgo biloba L."
 ]
}

 The dataset includes 735 records from 49 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055913-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29362847
title: Supplementary Material for: Comparative efficacy and safety of benzodiazepines in the treatment of patients with generalized anxiety disorder: a systematic review and network meta-analysis

description: Introduction
Guidelines recommend that benzodiazepines (BZD) might be used as an add-on to antidepressant therapy during the first weeks of treatment of generalized anxiety disorder (GAD) or as a first-line and stand-alone. Our aim is to evaluate the comparative efficacy and safety of individual BZD in the treatment of patients with GAD.
Methods
In this systematic review and network meta-analysis, we included randomized controlled trials including adults (≥18 years) with GAD and comparing BZD against placebo or an active intervention. We assessed the certainty of evidence using the confidence in network meta-analysis (CINeMA) framework. This study is registered with PROSPERO (registration number CRD42022330264).
Results
We included 56 studies (7556 participants). The certainty of the evidence for the primary outcomes, as measured with CINeMA, varied from high to very low (overall; 40 comparisons scored “very low”, 7 scored “low” and 814 scored “high”). Regarding efficacy, all BZD, in general, were significantly better than placebo, but there were no significant differences between the different BZD (high heterogeneity and inconsistency were detected). Regarding treatment discontinuation, with some exceptions, no significant differences were observed in the comparisons against placebo or other BZD (no or low heterogeneity and inconsistency were observed in the different analyses). Regarding treatment tolerability, none of the BZD showed significant differences compared to placebo, except diazepam (RR=1.61; 95%CI=1.32;1.96). Moderate heterogeneity and low inconsistency were observed in the treatment tolerability network meta-analysis.
Conclusion
BZD are overall efficacious for the treatment of GAD and have a favourable safety profile. No distinctive differences were identified when comparing BZD among themselves.
DOI: 10.6084/m9.figshare.29362847.v1
title: Supplementary Material for: Comparative efficacy and safety of benzodiazepines in the treatment of patients with generalized anxiety disorder: a systematic review and network meta-analysis

description: Introduction
Guidelines recommend that benzodiazepines (BZD) might be used as an add-on to antidepressant therapy during the first weeks of treatment of generalized anxiety disorder (GAD) or as a first-line and stand-alone. Our aim is to evaluate the comparative efficacy and safety of individual BZD in the treatment of patients with GAD.
Methods
In this systematic review and network meta-analysis, we included randomized controlled trials including adults (≥18 years) with GAD and comparing BZD against placebo or an active intervention. We assessed the certainty of evidence using the confidence in network meta-analysis (CINeMA) framework. This study is registered with PROSPERO (registration number CRD42022330264).
Results
We included 56 studies (7556 participants). The certainty of the evidence for the primary outcomes, as measured with CINeMA, varied from high to very low (overall; 40 comparisons scored “very low”, 7 scored “low” and 814 scored “high”). Regarding efficacy, all BZD, in general, were significantly better than placebo, but there were no significant differences between the different BZD (high heterogeneity and inconsistency were detected). Regarding treatment discontinuation, with some exceptions, no significant differences were observed in the comparisons against placebo or other BZD (no or low heterogeneity and inconsistency were observed in the different analyses). Regarding treatment tolerability, none of the BZD showed significant differences compared to placebo, except diazepam (RR=1.61; 95%CI=1.32;1.96). Moderate heterogeneity and low inconsistency were observed in the treatment tolerability network meta-analysis.
Conclusion
BZD are overall efficacious for the treatment of GAD and have a favourable safety profile. No distinctive differences were identified when comparing BZD among themselves.
DOI: 10.6084/m9.figshare.29362850
title: Supplementary Material for: Dihydroquercetin/Taxifolin inhibits METTL3/m6A/PIM2 expression by suppressing RIPK2 phosphorylation mediated NF-κB p65 signaling pathway to alleviates renal ischemia-reperfusion injury in mice

description: There is a close relationship between oxidative stress and renal ischemia-reperfusion injury (RIRI). Dihydroquercetin (DHQ, also konown as Taxifolin) can reduce kidney damage, and suppress cellular damage caused by oxidative stress. This study aimed to investigated the effects and underlying mechanisms of DHQ on RIRI. Firstly, hypoxia/reoxygenation (H/R) treated HK-2 cells were used for RIRI in vitro experiments, and the dosage of DHQ was selected by observing cell viability and lactate dehydrogenase (LDH) release. The protective effects of DHQ were evaluated by detecting cell apoptosis, reactive oxygen species (ROS) levels, and oxidative stress indicators levels. Our data suggested that DHQ inhibited cell apoptosis, ROS levels, and oxidative stress of H/R treated HK-2 cells. PIM2 regulates cell survival and proliferation, and H/R treatment up-regulated PIM2 levels. Over-expression of PIM2 partly reversed the effects of DHQ on protecting HK-2 cells after H/R induction, and promoted RIPK2 phosphorylation mediated NF-κB p65 signaling pathway. Additionally, METTL3 is an N6-methyladenosine (m6A) writer, and DHQ suppressed its expression in H/R treated HK-2 cells. METTL3 was enriched in PIM2 mRNA by m6A modification and stabilized the expression of PIM2. As for in vivo experiments, DHQ also inhibited the PIM2 level in mice kidney tissues and alleviated the kidney damage caused by RIRI. These effects were manifested in the reduction of renal injury markers, the reduction of oxidative stress levels, and the results of renal tissue HE staining. DHQ also suppressed PIM2 mediated RIPK2 phosphorylation mediated NF-κB p65 signaling pathway in renal tissues. Taken together, DHQ inhibited PIM2 levels by suppressing METTL3 mediated m6A modification to protect HK-2 cells from H/R induced injury, and this may be related to the regulation of PIM2 on RIPK2 phosphorylation mediated NF-κB p65 signaling pathway. This study suggested that DHQ may be a promising drug to treat RIRI, and may be useful for finding effective therapeutic targets in RIRI.
DOI: 10.6084/m9.figshare.29362850.v1
title: Supplementary Material for: Dihydroquercetin/Taxifolin inhibits METTL3/m6A/PIM2 expression by suppressing RIPK2 phosphorylation mediated NF-κB p65 signaling pathway to alleviates renal ischemia-reperfusion injury in mice

description: There is a close relationship between oxidative stress and renal ischemia-reperfusion injury (RIRI). Dihydroquercetin (DHQ, also konown as Taxifolin) can reduce kidney damage, and suppress cellular damage caused by oxidative stress. This study aimed to investigated the effects and underlying mechanisms of DHQ on RIRI. Firstly, hypoxia/reoxygenation (H/R) treated HK-2 cells were used for RIRI in vitro experiments, and the dosage of DHQ was selected by observing cell viability and lactate dehydrogenase (LDH) release. The protective effects of DHQ were evaluated by detecting cell apoptosis, reactive oxygen species (ROS) levels, and oxidative stress indicators levels. Our data suggested that DHQ inhibited cell apoptosis, ROS levels, and oxidative stress of H/R treated HK-2 cells. PIM2 regulates cell survival and proliferation, and H/R treatment up-regulated PIM2 levels. Over-expression of PIM2 partly reversed the effects of DHQ on protecting HK-2 cells after H/R induction, and promoted RIPK2 phosphorylation mediated NF-κB p65 signaling pathway. Additionally, METTL3 is an N6-methyladenosine (m6A) writer, and DHQ suppressed its expression in H/R treated HK-2 cells. METTL3 was enriched in PIM2 mRNA by m6A modification and stabilized the expression of PIM2. As for in vivo experiments, DHQ also inhibited the PIM2 level in mice kidney tissues and alleviated the kidney damage caused by RIRI. These effects were manifested in the reduction of renal injury markers, the reduction of oxidative stress levels, and the results of renal tissue HE staining. DHQ also suppressed PIM2 mediated RIPK2 phosphorylation mediated NF-κB p65 signaling pathway in renal tissues. Taken together, DHQ inhibited PIM2 levels by suppressing METTL3 mediated m6A modification to protect HK-2 cells from H/R induced injury, and this may be related to the regulation of PIM2 on RIPK2 phosphorylation mediated NF-κB p65 signaling pathway. This study suggested that DHQ may be a promising drug to treat RIRI, and may be useful for finding effective therapeutic targets in RIRI.
DOI: 10.6084/m9.figshare.29362853
title: Supplementary Material for: Case Report: Endocrine manifestations in Kearns-Sayre syndrome

description: Introduction: Kearns–Sayre syndrome [KSS] is a rare disorder caused by mutations in mitochondrial DNA. Some patients with mitochondrial diseases exhibit endocrine manifestations, the most frequent of which diabetes mellitus. 
Case Presentation: We report a case of a 20-year-old male, who initially presented with growth failure. At age 11 years, he experienced progressive vision loss, bilateral ptosis and ophthalmoplegia, cerebellar ataxia, delays in fine motor skills, dysmetria, fatigue and exercise intolerance. Initial medical work-up demonstrated elevated protein levels in the cerebrospinal fluid, cone-rod dystrophy, delayed bone age and low insulin-like growth factor-1. Enhanced cerebral magnetic resonance imaging revealed abnormal findings in the cerebellar white matter and mesencephalon. A third-degree atrioventricular block led to the need for a pacemaker placement. Subsequently, the patient was diagnosed with secondary hypothyroidism and hypogonadism. Polymerase chain reaction [PCR] sequencing revealed a large-scale mitochondrial DNA deletion. Hormone replacement therapy was initiated for endocrinopathies. However, his growth did not improve after recombinant human growth hormone treatment.
Conclusion: Endocrine manifestations are frequent and can be the first signs of KSS. However, this case emphasizes that KSS may present with growth failure years before other manifestations of the disease and underscores the rare coexistence of Kearns–Sayre syndrome and hypopituitarism. Maintaining a high level of suspicion is crucial for achieving an accurate and timely diagnosis, and a multidisciplinary follow-up is essential for the better management of these patients.
DOI: 10.6084/m9.figshare.29362853.v1
title: Supplementary Material for: Case Report: Endocrine manifestations in Kearns-Sayre syndrome

description: Introduction: Kearns–Sayre syndrome [KSS] is a rare disorder caused by mutations in mitochondrial DNA. Some patients with mitochondrial diseases exhibit endocrine manifestations, the most frequent of which diabetes mellitus. 
Case Presentation: We report a case of a 20-year-old male, who initially presented with growth failure. At age 11 years, he experienced progressive vision loss, bilateral ptosis and ophthalmoplegia, cerebellar ataxia, delays in fine motor skills, dysmetria, fatigue and exercise intolerance. Initial medical work-up demonstrated elevated protein levels in the cerebrospinal fluid, cone-rod dystrophy, delayed bone age and low insulin-like growth factor-1. Enhanced cerebral magnetic resonance imaging revealed abnormal findings in the cerebellar white matter and mesencephalon. A third-degree atrioventricular block led to the need for a pacemaker placement. Subsequently, the patient was diagnosed with secondary hypothyroidism and hypogonadism. Polymerase chain reaction [PCR] sequencing revealed a large-scale mitochondrial DNA deletion. Hormone replacement therapy was initiated for endocrinopathies. However, his growth did not improve after recombinant human growth hormone treatment.
Conclusion: Endocrine manifestations are frequent and can be the first signs of KSS. However, this case emphasizes that KSS may present with growth failure years before other manifestations of the disease and underscores the rare coexistence of Kearns–Sayre syndrome and hypopituitarism. Maintaining a high level of suspicion is crucial for achieving an accurate and timely diagnosis, and a multidisciplinary follow-up is essential for the better management of these patients.
DOI: 10.6084/m9.figshare.26999464
title: Figure 1

description: <b>Figure 1</b><b> | Selective astrocytic expression and in vitro activation of hM3Dq in astro-hM3Dq mice.</b> a, Schematic depicting the targeting strategy used to obtain tamoxifen-inducible Cre-dependent expression of hM3Dq selectively in astrocytes. b, Representative immunostaining images of astro-hM3Dq-positive mice showing Hoechst nuclear stain (blue), Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) that are tagged with a hemagglutinin (HA, green), and glial fibrillary acidic protein (GFAP, red). c, Representative astro-hM3Dq positive immunostaining image (40x) indicating Hoechst, DREADD HA-epitope, GFAP, merged image, and zoomed-in image indicating an example of HA-positive astrocyte. d, Representative immunostaining images of control mice showing Hoechst nuclear stain (blue), DREADD-HA epitope (green), and GFAP (red). e, Representative control immunostaining image (40x) indicating Hoechst, DREADD HA-epitope, GFAP, merged image, and zoomed-in image indicating an example of HA-negative astrocyte. f, Representative hippocampal astro-hM3Dq positive immunostaining image (40x) indicating DREADD HA-epitope, ionized calcium binding adaptor molecule 1 (Iba1), GFAP, merged image, and zoomed-in image indicating example of HA-positive astrocyte close to microglia (Cyan). g, Representative hippocampal astro-hM3Dq positive immunostaining image (40x) indicating DREADD HA-epitope, = (NeuN), GFAP, merged image, and zoomed in image indicating an example of HA-positive astrocyte close to a NeuN positive neuron (Cyan). h, hippocampal hM3Dq receptor expression in Iba1 positive cells (astro-hM3Dq n=5, control n=3). i, hippocampal hM3Dq receptor expression in NeuN positive cells (astro-hM3Dq n=5, control n=3). j, Astro-hM3Dq hippocampal expression (n=6). k, Astro-hM3Dq hippocampal specificity (n=6). l, In vitro calcium imaging experimental timeline. m-n, Kinetics of relative Rhod-2 fluorescence in cells in response to 5 µM clozapine N-oxide (CNO), 100 µM Adenosine triphosphate (ATP), and 2 µM ionomycin in 4-hydroxytamoxifen (4-OHT)-treated cultures in Krebs-Ringer-HEPES (KRH) buffer in m, astro-hM3Dq and n, astrocyte control cells. Scale bars: b, d = 200 ; c, e, f, g = 50 . Data are expressed as mean SEM. Unpaired, two-tailed Student t-test. **** &lt;0.0001.
DOI: 10.6084/m9.figshare.26999464.v1
title: Figure 1

description: <b>Figure 1</b><b> | Selective astrocytic expression and in vitro activation of hM3Dq in astro-hM3Dq mice.</b> a, Schematic depicting the targeting strategy used to obtain tamoxifen-inducible Cre-dependent expression of hM3Dq selectively in astrocytes. b, Representative immunostaining images of astro-hM3Dq-positive mice showing Hoechst nuclear stain (blue), Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) that are tagged with a hemagglutinin (HA, green), and glial fibrillary acidic protein (GFAP, red). c, Representative astro-hM3Dq positive immunostaining image (40x) indicating Hoechst, DREADD HA-epitope, GFAP, merged image, and zoomed-in image indicating an example of HA-positive astrocyte. d, Representative immunostaining images of control mice showing Hoechst nuclear stain (blue), DREADD-HA epitope (green), and GFAP (red). e, Representative control immunostaining image (40x) indicating Hoechst, DREADD HA-epitope, GFAP, merged image, and zoomed-in image indicating an example of HA-negative astrocyte. f, Representative hippocampal astro-hM3Dq positive immunostaining image (40x) indicating DREADD HA-epitope, ionized calcium binding adaptor molecule 1 (Iba1), GFAP, merged image, and zoomed-in image indicating example of HA-positive astrocyte close to microglia (Cyan). g, Representative hippocampal astro-hM3Dq positive immunostaining image (40x) indicating DREADD HA-epitope, = (NeuN), GFAP, merged image, and zoomed in image indicating an example of HA-positive astrocyte close to a NeuN positive neuron (Cyan). h, hippocampal hM3Dq receptor expression in Iba1 positive cells (astro-hM3Dq n=5, control n=3). i, hippocampal hM3Dq receptor expression in NeuN positive cells (astro-hM3Dq n=5, control n=3). j, Astro-hM3Dq hippocampal expression (n=6). k, Astro-hM3Dq hippocampal specificity (n=6). l, In vitro calcium imaging experimental timeline. m-n, Kinetics of relative Rhod-2 fluorescence in cells in response to 5 µM clozapine N-oxide (CNO), 100 µM Adenosine triphosphate (ATP), and 2 µM ionomycin in 4-hydroxytamoxifen (4-OHT)-treated cultures in Krebs-Ringer-HEPES (KRH) buffer in m, astro-hM3Dq and n, astrocyte control cells. Scale bars: b, d = 200 ; c, e, f, g = 50 . Data are expressed as mean SEM. Unpaired, two-tailed Student t-test. **** &lt;0.0001.
DOI: 10.15468/dl.w6yrnt
title: Occurrence Download

description: A dataset containing 613703 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Viola biflora L., Paeonia anomala L., Paris quadrifolia L., Geum rivale L., Carex cespitosa L.)",
 "Geometry POLYGON ((-180 45.53015, 180 45.53015, 180 83.62313, -180 83.62313, -180 45.53015))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "CoordinateUncertaintyInMeters is less than or equal to 50000"
 ]
}

 The dataset includes 613703 records from 723 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0055903-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.29vwfs
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Sousa chinensis taiwanensis Wang, Yang & Hung, 2015"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0066292-200221144449610/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.eyb9r0
title: Occurrence Download

description: A dataset containing 1313 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Geospiza conirostris Ridgway, 1890",
 "HasCoordinate is TRUE"
 ]
}

 The dataset includes 1313 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0035190-191105090559680/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7rzs28
title: Occurrence Download

description: A dataset containing 193947 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Peperomia Ruiz & Pav."
 ]
}

 The dataset includes 193947 records from 907 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0057043-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.38vedq
title: Occurrence Download

description: A dataset containing 1056 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Corynorhinus mexicanus G.M.Allen, 1916"
 ]
}

 The dataset includes 1056 records from 40 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060832-200221144449610/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.